Hepatocellular carcinoma [2]

New England Journal of Medicine

Volumn 366, Issue 1, 2012, Pages 92-

  Tsochatzis, Emmanuel A ^a   Meyer, Tim ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ECHOGRAPHY; HUMAN; HUMAN TISSUE; LETTER; LIVER CELL CARCINOMA; MEDICAL DECISION MAKING; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 84856158123     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1112501     Document Type: Letter

References (3)

1. Tsochatzis E, Meyer T, Marelli L, Burroughs AK. Which transarterial therapy is best for hepatocellular carcinoma? The evidence to date. J Hepatol 2010;53:588.
2. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6-25. (Pubitemid 44900485)
3. Meyer T, Roughton M, Yu D, et al. A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization (TACE) versus embolization (TAE) alone for hepatocellular cancer (HCC). J Clin Oncol 2010;28:Suppl 1:4025. abstract.